meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HR positive
es-BC - HR positive - (neo)adjuvant (NA)
2
es-BC - HR-positive - 1st line (L1)
1
la/mBC - HR positive
2
la/mBC - HR positive - (neo)adjuvant (NA)
3
la/mBC - HR positive - NA - PIK3CA mutant
la/mBC - HR-positive - 1st line (L1)
13
la/mBC - HR positive - L1 - PIK3CA mutant
1
la/mBC - HR-positive - 2nd line (L2)
20
la/mBC - HR positive - L2 - all population
1
la/mBC - HR positive - L2 - PIK3CA mutant
1
phosphoinositide 3-kinase (PI3K) inhibitor
buparlisib based treatment
buparlisib plus fulvestrant
versus all
vs endocrine therapy
vs fulvestrant
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
objective responses (ORR)
progression or deaths (PFS)
deaths (OS)
la/mBC - HR positive - L2 - all population
breast cancer - HR positive
la/mBC - HR positive
la/mBC - HR-positive - 2nd line (L2)
la/mBC - HR positive - L2 - all population
versus fulvestrant
buparlisib plus fulvestrant vs. fulvestrant
1
certainty unassessable
-12%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open